Signs of Alzheimer's disease progression: A clinical guide to understanding stages and care

Key facts

• Alzheimer's disease is a progressive neurological condition characterized by the accumulation of amyloid plaques and tau tangles in the brain 1 2.
• Clinical staging generally transitions from preclinical and mild cognitive impairment to mild, moderate, and severe dementia based on cognitive and functional decline 3 1.
• Medical management now includes both traditional symptom-targeting drugs and newer disease-modifying monoclonal antibody therapies that require regular monitoring 4 5.
• Total costs for dementia care in the United States, including medical and unpaid family care, are estimated to reach $818 billion in 2026 6.

Alzheimer's disease is a complex, progressive brain disorder that leads to a gradual decline in cognitive skills, memory, and functional independence 1. Understanding the clinical progression of the condition is essential for families and patients working with healthcare providers to develop effective management strategies. Because the disease is a continuous process that varies significantly from person to person, clinical staging helps professionals track changes in a patient's cognitive health and daily function over time 1.

The Clinical Stages of Alzheimer's Disease

Modern clinical staging has evolved to incorporate both behavioral symptoms and biological markers. While traditional systems relied primarily on cognitive assessment, current frameworks often integrate neuroimaging and fluid biomarkers, such as cerebrospinal fluid or blood-based testing, to identify amyloid-beta and tau pathology 3 7. The progression is generally categorized into five distinct stages that capture the transition from healthy brain function to severe dependence 1.

The preclinical stage can last for years or even decades, during which biological changes occur in the brain without any observable symptoms 1. This is followed by mild cognitive impairment (MCI), where patients may experience detectable cognitive decline while maintaining independence in daily activities 3 1. As the disease transitions into mild, moderate, and finally severe dementia, the accumulation of plaques and tangles causes widespread atrophy in the temporal, parietal, and frontal lobes, leading to increased loss of motor control, speech, and basic functional capabilities 2 8.

Diagnostic Processes and Professional Care

Diagnosis and long-term management are typically coordinated by specialists such as neurologists, geriatricians, and psychiatrists with expertise in memory disorders 3. These professionals use a combination of clinical interviews, cognitive testing, and advanced imaging to determine the stage of the disease. Specialized settings for care include outpatient memory clinics, hospital-based neurology departments, and dedicated long-term memory care facilities, all of which provide structured environments tailored to the specific needs of patients at different levels of progression 6.

Standard Treatment Options

Treatment approaches are currently divided into symptom management and disease-modifying therapies. Traditional medications, such as cholinesterase inhibitors like donepezil and rivastigmine, as well as NMDA receptor antagonists like memantine, are widely used to manage cognitive symptoms by temporarily supporting neurotransmitter function 9 5. These drugs are often considered highly cost-effective for symptom relief, though they do not address the underlying pathology of the disease 4.

Newer interventions, specifically anti-amyloid monoclonal antibodies such as lecanemab and donanemab, represent a significant shift in medical management. These drugs target the buildup of amyloid proteins in the brain and are designed to slow cognitive decline in the early stages of the disease 10 5. These treatments require rigorous clinical oversight, including regular MRI scans to monitor for potential side effects, such as brain swelling or bleeding, which are recognized risks associated with these potent therapies 10 5.

Financial Considerations and Costs

The economic impact of Alzheimer's disease is significant, with total costs in the United States estimated at $818 billion for 2026, accounting for medical care, long-term support, and the economic value of unpaid care provided by family members 6. Out-of-pocket costs vary widely based on the specific medication, insurance coverage, and the level of care required. For example, yearly treatments for monoclonal antibodies can cost $20,000 or more, while traditional symptom-management medications, such as generic donepezil or memantine, are generally less expensive, typically ranging from under $100 to hundreds of dollars for a 30-day supply 9.

Risks and Management Challenges

Clinical management of Alzheimer's disease involves balancing the potential benefits of treatments with the inherent risks. Patients receiving disease-modifying therapies must be carefully screened to ensure they meet strict eligibility criteria, such as confirmed amyloid pathology and an early-stage diagnosis 10. Because these therapies are not cures and carry risks like intracranial abnormalities, patient autonomy and ongoing consultation with a healthcare team are critical components of the decision-making process. The goal of current medical practice is to provide individualized care that accounts for the patient's specific disease stage, overall health, and personal goals 10 5.

Sources

1. Alzheimer's stages: How the disease progresses | Health Library | Memorial Health System: https://www.mhsystem.org/health-library/art-20048448/
2. Table 1 Progression of Alzheimer’s Disease: Neuropathological, Cognitive, and Functional Characteristics.: https://www.nature.com/articles/s41598-025-28070-x/tables/1
3. Stages of Alzheimer’s Disease| Alzheimer’s Disease | Healio: https://www.healio.com/clinical-guidance/alzheimers-disease/stages-of-alzheimer-s-disease-overview
4. Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review: https://exa.ai/library/publication/h7zrbc425km
5. What Patients Should Know About Emerging Alzheimer's Ther...: https://helpdementia.com/what-patients-should-know-about-emerging-alzheimers-therapies/
6. Dementia Will Cost the United States $818 Billion in 2026, USC-Led Study Finds – USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences: https://mann.usc.edu/news/dementia-will-cost-the-united-states-818-billion-in-2026-usc-led-study-finds/
7. Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies: https://www.psychiatryinvestigation.org/journal/view.php?number=2024
8. A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease | BMC Medicine | Springer Nature Link: https://link.springer.com/article/10.1186/s12916-026-04674-6
9. Cost and Insurance for Alzheimer's Disease: https://www.healthline.com/guides/memory-loss-alzheimers/caregiving/cost-and-insurance
10. Canada's Drug Agency recommends funding treatment for early-stage Alzheimer's disease: https://toronto.citynews.ca/2026/07/16/alzheimers-drug-coverage-canada-lecanemab/